The device distinguishes itself by offering physicians the flexibility to deploy either pulsed field ablation, radiofrequency energy, or a hybrid of both during cardiac procedures. This dual-energy approach allows medical teams to customize treatments based on individual patient requirements and the complexity of their specific arrhythmias. Clinical study results submitted to regulators demonstrated that the catheter maintains favorable safety and efficacy profiles for those suffering from abnormal heart rhythms.

Uri Yaron, senior vice president of Abbott’s electrophysiology business, noted that the device strengthens the company's ability to support physicians across the entire spectrum of patient care, ranging from initial diagnosis and mapping to advanced interventional procedures. By integrating this technology into its broader suite of ultrasound imaging and diagnostic tools, Abbott aims to solidify its footprint in the treatment of complex heart rhythm disorders.